Biohit Oyj OK'd to Start China Production of Cancer Screening Test

Biohit Oyj, a Finnish medical diagnostics company, reported that its China joint venture, Biohit HealthCare (Hefei), was granted a China production license for its GastroPanel® products. GastroPanel is a non-invasive test for low levels of acid in the stomach, a risk factor for gastric cancer. Low levels of stomach acid can be caused by H. pylori infection or dysfunction of the stomach mucosa (atrophic gastritis). The JV is 60% owned by China's Wisdom-Win. More details.... Stock Symbol: (HEL: BIOBV) Share this with colleagues: // //